OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 16:13 UTC. Every row links to its source record.

PALB2 partner and localizer of BRCA2

ENSG00000083093 · protein coding · Open Targets profile

Plays a critical role in homologous recombination repair (HRR) through its ability to recruit BRCA2 and RAD51 to DNA breaks (PubMed:16793542, PubMed:19369211, PubMed:19423707, PubMed:22941656, PubMed:24141787, PubMed:28319063). Strongly stimulates the DNA strand- invasion activity of RAD51, stabilizes the nucleoprotein filament against a disruptive BRC3-BRC4 polypeptide and helps RAD51 to overcome the suppressive effect of replication protein A (RPA) (PubMed:20871615). Functionally cooperates with RAD51AP1 in promoting of D-loop formation by RAD51 (PubMed:20871616). Serves as the molecular scaffold in the formation of the BRCA1-PALB2-BRCA2 complex which is essential for homologous recombination (PubMed:19369211). Via its WD repeats is proposed to scaffold a HR complex containing RAD51C and BRCA2 which is thought to play a role in HR-mediated DNA repair (PubMed:24141787). Essential partner of BRCA2 that promotes the localization and stability of BRCA2 (PubMed:16793542). Also enables its recombinational repair and checkpoint functions of BRCA2 (PubMed:16793542). May act by promoting stable association of BRCA2 with nuclear structures, allowing BRCA2 to escape the effects of proteasome-mediated degradation (PubMed:16793542). Binds DNA with high affinity for D loop, which comprises single-stranded, double-stranded and branched DNA structures (PubMed:20871616). May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with BRCA2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity (PubMed:24485656). {ECO:0000269|PubMed:16793542, ECO:0000269|PubMed:19369211, ECO:0000269|PubMed:19423707, ECO:0000269|PubMed:20871615, ECO:0000269|PubMed:20871616, ECO:0000269|PubMed:22941656, ECO:0000269|PubMed:24141787, ECO:0000269|PubMed:24485656, ECO:0000269|PubMed:28319063}.

In 13 of 15 cancers, the evidence for PALB2 comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751breast cancerbreast cancerbreast cancer: germline 0.96breast carcinomabreast carcinomabreast carcinoma: somatic 0.46breast carcinoma: germline 0.92breast neoplasmbreast neoplasmbreast neoplasm: germline 0.93hereditary breast ovarian cancer syndro…hereditary breast ovarian cancer syndromehereditary breast ovarian cancer syndrome: germline 0.94familial pancreatic carcinomafamilial pancreatic carcinomafamilial pancreatic carcinoma: germline 0.94hereditary breast carcinomahereditary breast carcinomahereditary breast carcinoma: germline 0.95susceptibility to breast cancersusceptibility to breast cancersusceptibility to breast cancer: germline 0.85PALB2-related cancer predispositionPALB2-related cancer predispositionPALB2-related cancer predisposition: germline 0.96bile duct adenocarcinomabile duct adenocarcinomabile duct adenocarcinoma: somatic 0.46bile duct adenocarcinoma: germline 0.87hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.95breast-ovarian cancer, familial, suscep…breast-ovarian cancer, familial, susceptibility to, 1breast-ovarian cancer, familial, susceptibility to, 1: germline 0.89gastric cancergastric cancergastric cancer: germline 0.88acute myeloid leukemiaacute myeloid leukemiaacute myeloid leukemia: somatic 0.46malignant pancreatic neoplasmmalignant pancreatic neoplasmmalignant pancreatic neoplasm: germline 0.64exocrine pancreatic carcinomaexocrine pancreatic carcinomaexocrine pancreatic carcinoma: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
High-Quality Pocket
PROTAC
Database Ubiquitination

gnomAD loss of function constraint: o/e 0.7636299729347229 (upper bound 0.9175900220870972). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of PALB2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of PALB2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.